Articles from May 2012
Posted by Site Administrator on May 31, 2012
As ALS Awareness Month 2012 comes to a close, Bob would like to ask one thing of everyone reading this: Make every day an ALS Awareness Day.
Categories: 501(c)(3) Non-Profit, Caretakers
| 
Tags: 501(c)(3) ALS charity, ALS, ALS Awareness Month, ALS charity, ALS community, ALS cure, ALS donations, ALS funding, ALS research, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, Henry Louis Gehrig, Lou Gehrig’s disease, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St. Louis Blues hockey, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis, The Iron Horse
| 
No comments
Posted by Site Administrator on May 30, 2012
Not only was Mr. Gehrig a study in baseball perfection, but also a model of courage and dignity.
Categories: 501(c)(3) Non-Profit
| Tags: 2130 consecutive games, 501(c)(3) ALS charity, ALS, ALS Awareness Month, ALS charity, ALS community, ALS cure, ALS donations, ALS funding, ALS research, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, Henry Louis Gehrig, Lou Gehrig’s disease, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis, The Iron Horse
| No comments
Posted by Site Administrator on May 29, 2012
Stevens thinks that their findings might shed light on diseases that involve synapse loss or dysfunction. In neurodegenerative diseases such as glaucoma, Alzheimer’s disease, Lou Gehrig’s disease (ALS), Huntington’s disease and Parkinson’s disease, scientists have noted subtle changes in synapses that might cause them to be targeted for elimination.
Categories: Research News
| Tags: 501(c)(3) ALS charity, ALS, ALS Awareness Month, ALS community, ALS research, ALS synapses, amyotrophic lateral sclerosis, Beth Stevens PhD, Bob Stehlin, Boston Children's Hospital, Dori Schafer PhD, he journal Neuron, immune cells, Kirby Neurobiology Center at Boston Children's Hospital, Lou Gehrig's disease, microglia, microglia receptors, neurodegenerative diseases, protein C3, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis
| No comments
Posted by Site Administrator on May 29, 2012
The easiest way to help is simply open your heart and open your wallet. We won’t kid you: the ALS community desperately needs funding.
Categories: 501(c)(3) Non-Profit, Caretakers, Research News, Treatments
| Tags: 501(c)(3) ALS charity, ALS, ALS Awareness Month, ALS charity, ALS community, ALS cure, ALS donations, ALS funding, ALS research, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, Lou Gehrig’s disease, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis
| No comments
Posted by Site Administrator on May 28, 2012
9 out of 10 people today still don’t know what ALS is about. Approximately 3 out of 10 (at best) have ever even heard of “ALS” or “Lou Gehrig’s disease.”
Categories: 501(c)(3) Non-Profit, Caretakers, Research News, Technology, Treatments
| Tags: 501(c)(3) ALS charity, ALS, ALS Awareness Month, ALS charity, ALS community, ALS cure, ALS donations, ALS funding, ALS research, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, Lou Gehrig’s disease, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis
| No comments
Posted by Site Administrator on May 27, 2012
Company requesting permission to evaluate efficacy in its phase 1 safety trial, as well as to increase the dosage and number of trial participants.
Categories: 501(c)(3) Non-Profit, Research News, Treatments
| Tags: 501(c)(3) ALS charity, ALS, ALS Awareness Month, ALS clinical trial, ALS community, ALS research, amyotrophic lateral sclerosis, Bob Stehlin, Lou Gehrig’s disease, mortality ALS, Neuralstem, PALS, Phase 1 safety efficacy, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis
| No comments
Posted by Site Administrator on May 27, 2012
Clearly the ALS community still has a long way to go to finding a cure, or even effective treatment options. And that’s also why fundraising is such an important part of what we do here at the RASCALS Foundation.
Categories: 501(c)(3) Non-Profit, Research News, Technology, Treatments
| Tags: 501(c)(3) ALS charity, additional ALS genes, ALS, ALS Awareness Month, ALS community, ALS medical care, ALS research, ALS survival rates, ALS treatments, amyotrophic lateral sclerosis, apoptosis, biological marker for ALS, Bob Stehlin, familial ALS, genetic risk factors ALS, Lou Gehrig’s disease, minocycline to treat ALS, mortality ALS, National Institute of Neurological Disorders and Stroke, neuroprotective strategies, neurotrophic factors, PALS, Potential therapies for ALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, SOD1 mutations, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis
| No comments
Posted by Site Administrator on May 26, 2012
There are people in whom ALS has stopped progressing and a small number of people in whom the symptoms of ALS reversed.
Categories: 501(c)(3) Non-Profit, Caretakers, Research News
| Tags: 501(c)(3) ALS charity, ALS, ALS Awareness Month, ALS community, ALS medical care, ALS research, ALS survival rates, ALS treatments, amyotrophic lateral sclerosis, Bob Stehlin, Lou Gehrig’s disease, mortality ALS, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis
| No comments
Posted by Site Administrator on May 25, 2012
ALS ultimately results in a total body paralysis, inability to speak, inability to eat or drink by mouth, and inability to breathe unassisted.
Categories: 501(c)(3) Non-Profit, Caretakers
| Tags: 501(c)(3) ALS charity, ALS, ALS Awareness Month, ALS caregiver, ALS community, ALS medical care, ALS research, ALS research funding, amyotrophic lateral sclerosis, Bob Stehlin, late stage ALS, Lou Gehrig’s disease, PALS, RASCALS Foundation, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis
| No comments
Posted by Site Administrator on May 24, 2012
Current treatment of ALS is aimed at symptomatic relief, prevention of complications and maintenance of maximum optimal function and optimal quality of life.
Categories: 501(c)(3) Non-Profit, Caretakers, Treatments
| Tags: 501(c)(3) ALS charity, ALS, ALS Awareness Month, ALS community, ALS medical care, ALS research, ALS treatments, amyotrophic lateral sclerosis, Lou Gehrig’s disease, PALS, RASCALS Foundation, Rilutek, riluzole, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis
| No comments
